PBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Sep. 2023, Pressure BioSciences spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Pressure BioSciences spent $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.
The historical data trend for Pressure BioSciences's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pressure BioSciences Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Cash Flow from Investing | Get a 7-Day Free Trial | - | -0.02 | -0.80 | -0.12 | -0.02 |
Pressure BioSciences Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Cash Flow from Investing | Get a 7-Day Free Trial | -0.02 | - | - | - | - |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Pressure BioSciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:
Pressure BioSciences's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pressure BioSciences (OTCPK:PBIO) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Pressure BioSciences's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $-0.00 Mil. It means Pressure BioSciences spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Pressure BioSciences's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Pressure BioSciences's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Pressure BioSciences's sale of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Pressure BioSciences's purchase of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Pressure BioSciences's sale of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences gained $0.00 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Pressure BioSciences's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Pressure BioSciences's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.00 Mil. It means Pressure BioSciences paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Pressure BioSciences's cash from other investing activities for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences paid $0.00 Mil for other investing activities.
Thank you for viewing the detailed overview of Pressure BioSciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Joseph Shea | officer: Senior Vice President & CFO | 2 MINUTEMAN ROAD, MEDFIELD MA 02052 |
Bradford Addison Young | officer: Chief Commercial Officer | 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405 |
Richard T Schumacher | director, officer: Chief Executive Officer | 375 WEST STREET, WEST BRIDGEWATER MA 02379 |
Nathan Lawrence | other: VP Sales and Marketing | 321 MANLEY STREET, WEST BRIDGEWATER MA 02379 |
Richard Thomley | officer: Chief Financial Officer | C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375 |
Kevin Pollack | director | 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689 |
Michael S Urdea | director | 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507 |
Alexander V Lazarev | officer: VP of REsearch and Development | 18 WINCHESTER DRIVE, LEXINGTON MA 02420 |
Edmund Y Ting | officer: Senior VP of Engineering | 23642 123RD PLACE SOUTHEAST, KENT WA 48031 |
Vito J Mangiardi | director | 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903 |
Jeffrey N Peterson | director | 1031 SHORELINE DRIVE, SAN MATEO CA 94404 |
Mir Conrad F | officer: CFO | 19 BRIER LANE, CLIFTON NJ 07012 |
Clayton A Struve | 10 percent owner | 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604 |
Css Llc/il | other: (a) | 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604 |
R Wayne Fritzsche | director | 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067 |
From GuruFocus
By sperokesalga sperokesalga • 06-01-2023
By ACCESSWIRE • 07-26-2023
By ACCESSWIRE • 08-30-2023
By ACCESSWIRE • 01-04-2024
By ACCESSWIRE ACCESSWIRE • 05-10-2023
By ACCESSWIRE • 08-22-2023
By ACCESSWIRE ACCESSWIRE • 06-01-2023
By ACCESSWIRE • 09-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.